Rheb/mTOR activation and regulation in cancer: Novel treatment strategies beyond rapamycin

Justin T. Babcock, Lawrence Quilliam

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this drug. These mTOR complexes play an integral role in the regulation of many cellular processes including protein synthesis, autophagy, lipid synthesis, mitochondrial metabolism/biogenesis, and cell cycle. Both mTOR complexes are important for maintaining cellular homeostasis and the growth of many types of cancer. Rapamycin and rapalogs have been effective in treating only a small number of these cancers, and other methods are being developed in order to address the short-comings of these drugs. The most direct of these approaches include ATP-competitive inhibitors of the mTOR kinase or dual inhibitors of both mTOR and PI3 kinase. However, other methods of inhibiting mTORC1 may prove clinically useful as well. These include amino acid depletion using asparaginase and inhibition of the Rheb GTPases with farnesyl transferase inhibitors or statins. Most excitingly, mTORC1 activation has been shown to cause and sensitize cells to DNA damage and ER stress. Many of the drugs currently used in the clinic for the treatment of cancer cause these types of stress, and existing drugs may be tailored to treat tumors with high mTORC1 activity.

Original languageEnglish
Pages (from-to)1223-1231
Number of pages9
JournalCurrent Drug Targets
Volume12
Issue number8
DOIs
StatePublished - Jul 2011

Fingerprint

Oncology
Sirolimus
Chemical activation
Pharmaceutical Preparations
Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Asparaginase
GTP Phosphohydrolases
Macrolides
Autophagy
Organelle Biogenesis
Transferases
Phosphatidylinositol 3-Kinases
Metabolism
DNA Damage
Tumors
Cell Cycle
Homeostasis
Phosphotransferases
Adenosine Triphosphate

Keywords

  • Cancer
  • Endoplasmic reticulum stress
  • Farnesyl transferase inhibitor
  • Mtor
  • Rapamycin
  • Rheb

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Rheb/mTOR activation and regulation in cancer : Novel treatment strategies beyond rapamycin. / Babcock, Justin T.; Quilliam, Lawrence.

In: Current Drug Targets, Vol. 12, No. 8, 07.2011, p. 1223-1231.

Research output: Contribution to journalArticle

@article{9c3023274e1f4d55b1433d674f414452,
title = "Rheb/mTOR activation and regulation in cancer: Novel treatment strategies beyond rapamycin",
abstract = "mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this drug. These mTOR complexes play an integral role in the regulation of many cellular processes including protein synthesis, autophagy, lipid synthesis, mitochondrial metabolism/biogenesis, and cell cycle. Both mTOR complexes are important for maintaining cellular homeostasis and the growth of many types of cancer. Rapamycin and rapalogs have been effective in treating only a small number of these cancers, and other methods are being developed in order to address the short-comings of these drugs. The most direct of these approaches include ATP-competitive inhibitors of the mTOR kinase or dual inhibitors of both mTOR and PI3 kinase. However, other methods of inhibiting mTORC1 may prove clinically useful as well. These include amino acid depletion using asparaginase and inhibition of the Rheb GTPases with farnesyl transferase inhibitors or statins. Most excitingly, mTORC1 activation has been shown to cause and sensitize cells to DNA damage and ER stress. Many of the drugs currently used in the clinic for the treatment of cancer cause these types of stress, and existing drugs may be tailored to treat tumors with high mTORC1 activity.",
keywords = "Cancer, Endoplasmic reticulum stress, Farnesyl transferase inhibitor, Mtor, Rapamycin, Rheb",
author = "Babcock, {Justin T.} and Lawrence Quilliam",
year = "2011",
month = "7",
doi = "10.2174/138945011795906589",
language = "English",
volume = "12",
pages = "1223--1231",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Rheb/mTOR activation and regulation in cancer

T2 - Novel treatment strategies beyond rapamycin

AU - Babcock, Justin T.

AU - Quilliam, Lawrence

PY - 2011/7

Y1 - 2011/7

N2 - mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this drug. These mTOR complexes play an integral role in the regulation of many cellular processes including protein synthesis, autophagy, lipid synthesis, mitochondrial metabolism/biogenesis, and cell cycle. Both mTOR complexes are important for maintaining cellular homeostasis and the growth of many types of cancer. Rapamycin and rapalogs have been effective in treating only a small number of these cancers, and other methods are being developed in order to address the short-comings of these drugs. The most direct of these approaches include ATP-competitive inhibitors of the mTOR kinase or dual inhibitors of both mTOR and PI3 kinase. However, other methods of inhibiting mTORC1 may prove clinically useful as well. These include amino acid depletion using asparaginase and inhibition of the Rheb GTPases with farnesyl transferase inhibitors or statins. Most excitingly, mTORC1 activation has been shown to cause and sensitize cells to DNA damage and ER stress. Many of the drugs currently used in the clinic for the treatment of cancer cause these types of stress, and existing drugs may be tailored to treat tumors with high mTORC1 activity.

AB - mTOR exists in two distinct complexes. mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this drug. These mTOR complexes play an integral role in the regulation of many cellular processes including protein synthesis, autophagy, lipid synthesis, mitochondrial metabolism/biogenesis, and cell cycle. Both mTOR complexes are important for maintaining cellular homeostasis and the growth of many types of cancer. Rapamycin and rapalogs have been effective in treating only a small number of these cancers, and other methods are being developed in order to address the short-comings of these drugs. The most direct of these approaches include ATP-competitive inhibitors of the mTOR kinase or dual inhibitors of both mTOR and PI3 kinase. However, other methods of inhibiting mTORC1 may prove clinically useful as well. These include amino acid depletion using asparaginase and inhibition of the Rheb GTPases with farnesyl transferase inhibitors or statins. Most excitingly, mTORC1 activation has been shown to cause and sensitize cells to DNA damage and ER stress. Many of the drugs currently used in the clinic for the treatment of cancer cause these types of stress, and existing drugs may be tailored to treat tumors with high mTORC1 activity.

KW - Cancer

KW - Endoplasmic reticulum stress

KW - Farnesyl transferase inhibitor

KW - Mtor

KW - Rapamycin

KW - Rheb

UR - http://www.scopus.com/inward/record.url?scp=79959311967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959311967&partnerID=8YFLogxK

U2 - 10.2174/138945011795906589

DO - 10.2174/138945011795906589

M3 - Article

C2 - 21561413

AN - SCOPUS:79959311967

VL - 12

SP - 1223

EP - 1231

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -